Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studies
Background and objectives: Although amyloid positron emission tomography (PET) and Cerebrospinal fluid (CSF) biomarkers remain the standard for confirming Alzheimer’s disease (AD) pathology, their use is impractical for screening or routine prognostic assessment. Plasma phosphorylated tau […]
Cognitive performance and blood biomarkers: Insights into their relationship and predicting high Amyloid Probability Score in cognitively impaired older adults
Background: Understanding associations between cognitive performance and blood biomarkers supports diagnosis and treatment of Alzheimer’s disease (AD); however, this relationship remains unclear. Objective: Exploring associations between the Amyloid Probability Score (APS; PrecivityAD® blood test) and cognitive […]
